SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-156202
Filing Date
2024-06-06
Accepted
2024-06-06 17:17:54
Documents
13
Period of Report
2024-06-05
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d844037d8k.htm   iXBRL 8-K 33441
  Complete submission text file 0001193125-24-156202.txt   155943

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20240605.xsd EX-101.SCH 2853
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20240605_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20240605_pre.xml EX-101.PRE 11263
16 EXTRACTED XBRL INSTANCE DOCUMENT d844037d8k_htm.xml XML 3653
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 241026432
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)